Literature DB >> 25773849

Importance of PET/CT scan use in planning radiation therapy for lymphoma.

Mitric-Askovic Milana1, Erak Marko, Latinovic Miroslav, Dugandzija Tihomir.   

Abstract

BACKGROUND: Radiation therapy is a key part of the combined modality treatment for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), which can achieve locoregional control of disease. The 3D-conformal radiation oncology can be extended-field (EFRT), involved-field (IFRT) and involved node (INRT). New techniques have resulted in a smaller radiation field and lower dose for critical organs such as lung heart and breast.
MATERIALS AND METHODS: In our research, we made a virtual simulation for one patient who was treated in four different radiotherapeutic techniques: mantle field (MFRT), EFRT, IFRT and INRT. After delineatiion we compared dose-volume histograms for each technique. The fusion of CT for planning radiotherapy with the initial PET/CT was made using Softver Xio 4.6 in the Focal program. The dose for all four techniques was 36Gy.
RESULTS: Our results support the use of PET/CT in radiation therapy planning. With IFRT and INRT, the burden on the organs at risk is less than with MFRT and EFRT. On the other hand, the dose distribution in the target volume is much better with the latter.
CONCLUSIONS: The aim of modern radiotherapy of HL and NHL is to reduce the intensity of treatment and therefore PET/CT should be used to reduce and not increase the amount of tissue receiving radiation.

Entities:  

Mesh:

Year:  2015        PMID: 25773849     DOI: 10.7314/apjcp.2015.16.5.2051

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  1 in total

1.  Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols.

Authors:  Maseeh Uz Zaman; Nosheen Fatima; Areeba Zaman; Unaiza Zaman; Sidra Zaman; Rabia Tahseen
Journal:  Asian Pac J Cancer Prev       Date:  2020-08-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.